Sema4 (NASDAQ:SMFR – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The brokerage currently has a $2.00 price objective on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 17.65% from the stock’s previous close.
According to Zacks, “Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn. “
Other analysts have also recently issued reports about the company. Cowen reduced their price target on Sema4 from $13.00 to $5.00 in a report on Monday, May 16th. Compass Point decreased their price target on shares of Sema4 to $5.00 and set a “na” rating on the stock in a research note on Monday, May 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $7.50.
Sema4 (NASDAQ:SMFR – Get Rating) last announced its earnings results on Monday, March 14th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. The firm had revenue of $57.80 million for the quarter, compared to analysts’ expectations of $50.90 million. Equities research analysts predict that Sema4 will post -0.76 EPS for the current fiscal year.
In other news, CFO Isaac Ro sold 19,515 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $2.46, for a total value of $48,006.90. Following the completion of the sale, the chief financial officer now directly owns 201,786 shares in the company, valued at approximately $496,393.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Tactical Opportunit Blackstone bought 2,500,000 shares of the company’s stock in a transaction on Friday, April 29th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the insider now directly owns 26,839,187 shares of the company’s stock, valued at approximately $107,356,748. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 14,037,500 shares of company stock valued at $55,942,000 and sold 33,099 shares valued at $79,156.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Deerfield Management Company L.P. Series C increased its position in Sema4 by 0.9% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 13,966,824 shares of the company’s stock valued at $62,292,000 after acquiring an additional 118,336 shares during the period. SB Management Ltd bought a new position in shares of Sema4 in the third quarter worth $68,473,000. Vanguard Group Inc. raised its stake in shares of Sema4 by 67.6% during the first quarter. Vanguard Group Inc. now owns 5,518,333 shares of the company’s stock valued at $16,941,000 after purchasing an additional 2,226,502 shares in the last quarter. Casdin Capital LLC acquired a new stake in Sema4 in the third quarter worth about $37,950,000. Finally, Third Point LLC grew its position in Sema4 by 53.7% in the 4th quarter. Third Point LLC now owns 4,295,000 shares of the company’s stock valued at $19,156,000 after buying an additional 1,500,000 shares in the last quarter.
About Sema4 (Get Rating)
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.
- Get a free copy of the StockNews.com research report on Sema4 (SMFR)
- Investors Can Get 5%-Plus Dividend Yields on These 3 Buys
- It’s Time to Buy into Planet Fitness Stock
- Indie Semiconductor Stock is Putting in a Bottom
- Two Retailers, One To Buy And One To Avoid
- 3 Defensive Consumer Stocks Worth Shopping For
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.